Form 4: VolitionRx CEO Plans 15,000 Share Purchase
Insider Transaction Report
VolitionRx CEO Cameron John Reynolds reported a planned acquisition of 15,000 shares of common stock at $0.659 per share, scheduled for September 12, 2025.
Summary
- Cameron John Reynolds, President and CEO, and a Director of VolitionRx Ltd. (VNRX), reported an upcoming acquisition of 15,000 shares of common stock.
- This transaction is scheduled to occur on September 12, 2025, at a price of $0.659 per share.
- The purchase is being made pursuant to a pre-arranged Rule 10b5-1(c) trading plan.
- Following this planned transaction, Mr. Reynolds' direct beneficial ownership will be 2,624,847 shares of common stock.
- He also indirectly beneficially owns 1,007,718 shares through Concord International, Inc., and 34,076 shares through his spouse.
Sentiment
Score: 8
Explanation: The planned insider purchase by the CEO signals strong confidence in the company's future prospects and valuation, which is a positive indicator for investors.
Positives
- The President and CEO, Cameron John Reynolds, has reported a planned purchase of 15,000 shares of company common stock, signaling confidence in the company's future prospects.
- The transaction is executed under a Rule 10b5-1(c) plan, indicating a pre-planned acquisition strategy and potentially a long-term positive outlook.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: May view the CEO's planned purchase as a positive signal, potentially increasing investor confidence in the company's future.
- Management/Employees: Reinforces alignment of interests between leadership and company performance, potentially boosting morale.
Key Dates
| Date | Description |
|---|---|
| 09/12/2025 | Planned date of transaction for Cameron John Reynolds to acquire 15,000 shares of common stock. |
| 09/15/2025 | Date the Form 4 was signed and filed, reporting the planned transaction. |
Recommendation
buyThe filing reports a planned future purchase of company stock by the President and CEO under a 10b5-1 plan. This pre-scheduled insider buying, while not immediate, still reflects a long-term positive conviction in the company's prospects and valuation, which is generally a bullish signal for investors.
Keywords
VNRX, VolitionRx, insider trading, stock purchase, CEO, Form 4, common stock, Cameron John Reynolds, 10b5-1 plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.